Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

Current health news includes Trump considering protective measures for gas appliances against regulatory changes. The WHO ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

Find insight on China’s healthcare sector, Wuxi Biologics and more in the latest Market Talks covering the Health Care sector ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...